Santero Therapeutics

TLDR

Santero Therapeutics develops first-in-class medicines targeting dormant bacteria in chronic infections by modulating RelA/SpoT homolog enzymes.

Overview

Santero Therapeutics focuses on breaking the cycle of chronic infections, particularly in conditions like non-cystic fibrosis bronchiectasis where bacteria establish persistent colonies resistant to standard treatments. The company discovered a master switch controlling bacterial dormancy (RSH enzymes) and is developing small molecules with bactericidal activity to target these persistent bacteria.